CDKN2A and large cell neuroendocrine carcinoma: performed next-generation sequencing (NGS) and determined the TP53, RB1, STK-11, KEAP-1, and IHC for RB1 and P16 in patients with LCNEC and correlated mutations with treatment and clinical outcomes.